Boundless Bio (BOLD) Other Accumulated Expenses (2023 - 2026)

Boundless Bio (BOLD) has reported Other Accumulated Expenses for 4 consecutive years, with $396000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 55.1% year-over-year to $396000.0; the TTM figure through Mar 2026 stood at $396000.0 (down 55.1% YoY), while the FY2025 annual figure was $517000.0, down 65.44% from the prior year.
• Other Accumulated Expenses eased to $396000.0 in Q1 2026 per BOLD's latest filing, from $517000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.5 million in Q1 2024 and bottomed at $396000.0 in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $968100.0 across 4 years, with a median of $901500.0 in 2025.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses surged 218.98% — and 2025, when it slumped 65.44%.
• Boundless Bio's Other Accumulated Expenses stood at $469000.0 in 2023, then soared by 218.98% to $1.5 million in 2024, then plunged by 65.44% to $517000.0 in 2025, then retreated by 23.4% to $396000.0 in 2026.
• Business Quant data shows BOLD's Other Accumulated Expenses at $396000.0 in Q1 2026, $517000.0 in Q4 2025, and $921000.0 in Q3 2025.